Physical resilience is a predictor of healthy aging
Physical resilience is a predictor of healthy aging
批准号:
10731992
负责人:
Warren C LADIGES
金额:
$67.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-15 至 2028-04-30
关键词:
AcuteAgeAgingAreaBiological AssayBiometryBiopsyBody fatCategoriesCellsCharacteristicsClassificationClinical ResearchCutaneousCyclophosphamideDataDiabetes MellitusDiseaseEarElderlyEvaluationFundingGoalsGrantHealthHeart DiseasesImmunohistochemistryImpaired cognitionIndividualInsulin ResistanceInterventionInvestigationLearningLesionLifeLymphocyteMalignant NeoplasmsMeasuresMemoryMemory LossMolecularMolecular AnalysisMusMuscleOrganParentsPathologicPathway AnalysisPathway interactionsPatientsPatternPeripheralPharmaceutical PreparationsPhenotypePhysically ChallengedPhysiologicalPredispositionProteinsPublic HealthPunch BiopsyResistanceRheumatoid ArthritisRisk FactorsSleep disturbancesStressStressful EventSystemTherapeuticThinnessTissuesTraumaWound modelsage relatedbiological adaptation to stresschemotherapeutic agentdesigndigital imaginggene producthealinghealthy aginghuman old age (65+)individual variationluminescencemiddle agemolecular imagingmuscle formnanoscaleneutrophilpre-clinicalpromote resilienceprotective factorsresilienceresponsestressortherapeutic targettissue repairtraittranscriptome sequencingtranscriptomicswound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract Physical resilience is a predictor of healthy aging (Competitive renewal)
The ability to respond to and recover from a physically stressful event is defined as physical resilience. The
inherent individual variation in response to a physical stressor suggests that different stressors trigger different
stress response patterns. A deeper understanding as to why some individuals maintain or regain function
following an insult, while others do not, may help to characterize protective factors that can be engaged to
promote resilience and healthy aging. We have developed and partially characterized three translationally
relevant physical stressors in mice: acute sleep disruption (ASD), the chemotherapeutic drug
cyclophosphamide (CYP), and acute cutaneous trauma (ACT), that trigger responses showing a correlation
with physiological and pathological features associated with increasing age. We have shown in the first grant
period that ASD, CYP, and ACT administered to middle-aged mice results in a range of responsiveness from
low to high, such that mice can be categorized as resistant or susceptible and aligned with phenotypic and
geropathologic parameters of aging. The hypothesis of the competitive renewal is that resilience to aging
is characterized by heterogeneous response patterns unique to defined physical stressors in an age-
dependent manner. Aim 1 is designed to validate physiological targets of ASD, CYP, and ACT.
Responsiveness will be determined by readout assays (escape times in a learning task for ASD, neutrophil to
lymphocyte ratio for CYP, and biopsy healing area for ACT) in middle aged mice as resistant or susceptible to
each physical stressor. Each group of mice will then be followed to older age and aligned with phenotypic
aging endpoints including assessments for memory, strength and agility. Aim 2 is designed to confirm organ-
based targets of ASD, CYP, and ACT in tissues from Aim 1 mice using endpoints based on differences in
geropathology lesion scores in specific organs from the two groups. Digital imaging and biostatistical
paradigms for mouse PathoClock analyses will be used for evaluation of organ-specific and organ-common
geropathology data. Aim 3 is designed to identify and characterize molecular pathways of ASD, CYP, and ACT
in tissues from Aim 1 mice and employ RNA seq for transcriptomic pathway analysis followed by verification
with nanoscale protein analytical platforms and immunohistochemistry imaging for molecular analysis of
relevant pathways in stress resistant and stress susceptible mice. The data can then be aligned with data from
Aims 1 and 2. Investigations into the molecular pathways utilized by cells in a particular tissue and organ in
response to a physical stressor would be of merit in individuals predicted to be less resilient to aging and would
have impactful significance for designing clinical studies to enhance healthy aging.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.31491/apt.2020.09.035
发表时间:
2020-09-29
期刊:
Aging pathobiology and therapeutics
影响因子:
--
作者:
[Oveson R, Jiang Z, Izhaky M, Sharma K, Ladiges WC]
通讯作者:
Ladiges WC
DOI:
10.31491/apt.2020.12.046
发表时间:
2020-12-31
期刊:
Aging pathobiology and therapeutics
影响因子:
--
作者:
[Nickel K, Bjorner M, Ladiges W, Zhu L]
通讯作者:
Zhu L
DOI:
10.31491/apt.2020.03.014
发表时间:
2020-03-27
期刊:
Aging pathobiology and therapeutics
影响因子:
--
作者:
[Dou Y, Lee A, Zhu L, Morton J, Ladiges W]
通讯作者:
Ladiges W
DOI:
10.31491/apt.2021.03.051
发表时间:
2021-03-29
期刊:
Aging pathobiology and therapeutics
影响因子:
--
作者:
[Ellis M, Ladiges W, Jiang Z]
通讯作者:
Jiang Z
Wheel running predicts resilience to tumors in old mice.
轮子运转预测老年小鼠对肿瘤的恢复能力。
DOI:
10.1080/20010001.2019.1676104
发表时间:
2019
期刊:
Pathobiology of aging & age related diseases
影响因子:
--
作者:
[Zhu,Lida, Wang,Juan, Pettan-Brewer,Christina, Ladiges,Warren, Goh,Jorming]
通讯作者:
Goh,Jorming
共 26 条
Physical resilience is a predictor of healthy aging in mice
-
批准号:9418968
-
项目类别:
-
资助金额:$31.78万
-
财政年份:2017
-
负责人:Warren C LADIGES
-
依托单位:
Physical resilience is a predictor of healthy aging in mice
-
批准号:10166752
-
项目类别:
-
资助金额:$31.78万
-
财政年份:2017
-
负责人:Warren C LADIGES
-
依托单位:
Pathology of Aging Research Network
-
批准号:9063461
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2014
-
负责人:Warren C LADIGES
-
依托单位:
Pathology of Aging Research Network
-
批准号:8665573
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2014
-
负责人:Warren C LADIGES
-
依托单位:
Pathology of Aging Research Network
-
批准号:8846003
-
项目类别:
-
资助金额:$37.47万
-
财政年份:2014
-
负责人:Warren C LADIGES
-
依托单位:
Mitochondrial catalase as a treatment for metastatic breast cancer
-
批准号:7707170
-
项目类别:
-
资助金额:$17.16万
-
财政年份:2009
-
负责人:Warren C LADIGES
-
依托单位:
Cancer susceptibility of XRCC1 mutant mice
-
批准号:7439285
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2008
-
负责人:Warren C LADIGES
-
依托单位:
Cancer susceptibility of XRCC1 mutant mice
-
批准号:7609207
-
项目类别:
-
资助金额:$23.4万
-
财政年份:2008
-
负责人:Warren C LADIGES
-
依托单位:
CORE--Transgenic Animal Support
-
批准号:6880488
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2005
-
负责人:Warren C LADIGES
-
依托单位:
Alzheimer's Disease and Impaired APP Proteolysis
-
批准号:7140287
-
项目类别:
-
资助金额:$19.37万
-
财政年份:2005
-
负责人:Warren C LADIGES
-
依托单位:
CORE--TRANSGENIC ANIMAL MODEL DEVELOPMENT
-
批准号:6948119
-
项目类别:
-
资助金额:$15.66万
-
财政年份:2005
-
负责人:Warren C LADIGES
-
依托单位:
Alzheimer's Disease and Impaired APP Proteolysis
-
批准号:6960182
-
项目类别:
-
资助金额:$16.52万
-
财政年份:2005
-
负责人:Warren C LADIGES
-
依托单位:
Mouse Core
-
批准号:6990384
-
项目类别:
-
资助金额:$10.27万
-
财政年份:2004
-
负责人:Warren C LADIGES
-
依托单位:
CORE--TRANSGENIC ANIMAL MODEL DEVELOPMENT
-
批准号:6651691
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2002
-
负责人:Warren C LADIGES
-
依托单位:
CORE--TRANSGENIC ANIMAL MODEL DEVELOPMENT
-
批准号:6613334
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2002
-
负责人:Warren C LADIGES
-
依托单位:
CORE--TRANSGENIC ANIMAL SUPPORT
-
批准号:6577784
-
项目类别:
-
资助金额:$7.35万
-
财政年份:2002
-
负责人:Warren C LADIGES
-
依托单位:
CORE--TRANSGENIC ANIMAL MODEL DEVELOPMENT
-
批准号:6605428
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2002
-
负责人:Warren C LADIGES
-
依托单位:
CORE--TRANSGENIC ANIMAL SUPPORT
-
批准号:6438205
-
项目类别:
-
资助金额:$11.79万
-
财政年份:2001
-
负责人:Warren C LADIGES
-
依托单位:
Comparative Mouse Genomics Center
-
批准号:6603306
-
项目类别:
-
资助金额:$120.65万
-
财政年份:2001
-
负责人:Warren C LADIGES
-
依托单位:
Comparative Mouse Genomics Center
-
批准号:6619142
-
项目类别:
-
资助金额:$5.23万
-
财政年份:2001
-
负责人:Warren C LADIGES
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: